Systolic heart failure: A prothrombotic state

Seminars in Thrombosis and Hemostasis

Volumn 35, Issue 5, 2009, Pages 497-504

  De Peuter, Olav R ^a   Kok, Wouter E M ^a   Torp Pedersen, Christian ^b   Büller, Harry R ^a   Kamphuisen, Pieter W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Anticoagulants; Heart failure; Hemostasis; Platelet aggregation inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CLOPIDOGREL; DICOUMAROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETHYL BISCOUMACETATE; HEPARIN; IVABRADINE; METOPROLOL; WARFARIN;

ADRENERGIC SYSTEM; ANTICOAGULANT THERAPY; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SYSTOLIC HEART FAILURE; THROMBOEMBOLISM;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; ASPIRIN; FIBRINOLYTIC AGENTS; HEART FAILURE, SYSTOLIC; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; THROMBOEMBOLISM; WARFARIN;

EID: 70449416759     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1234145     Document Type: Review

References (57)

1. McMurray J J., Petrie M C., Murdoch D R., Davie A P. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998 19 (suppl P) P9-P16
2. Davis R C., Hobbs F D., Lip G Y. ABC of heart failure. History and epidemiology. BMJ 2000 320 (7226) 39-42
3. Lip G Y., Chung I. Anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. QJM 2002 95 (7) 451-459
4. Lip G Y., Chung I. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. QJM 2002 95 (7) 461-468
5. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987 316 (23) 1429-1435
6. Køber L, Torp-Pedersen C. Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study. Am J Cardiol 1995 76 (1) 1-5
7. McMurray J, McDonagh T, Morrison C E., Dargie H J. Trends in hospitalization for heart failure in Scotland 19801990. Eur Heart J 1993 14 (9) 1158-1162
8. Cleland J G., Gemmell I, Khand A, Boddy A. Is the prognosis of heart failure improving? Eur J Heart Fail 1999 1 (3) 229-241
9. Mosterd A, Hoes A W. Clinical epidemiology of heart failure. Heart 2007 93 (9) 1137-1146
10. Chung I, Lip G Y. Antithrombotic therapy for congestive heart failure. Int J Clin Pract 2006 60 (1) 36-47
11. Pullicino P, Thompson J L., Barton B, Levin B, Graham S, Freudenberger R S., WARCEF Investigators. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. J Card Fail 2006 12 (1) 39-46
12. Witt B J., Gami A S., Ballman K V. et al. The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail 2007 13 (6) 489-496
13. Fox K, Ford I, Steg P G., Tendera M, Ferrari R, BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008 372 (9641) 807-816
14. Orn S, Cleland J G., Romo M, Kjekshus J, Dickstein K. Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. Am J Med 2005 118 (7) 752-758
15. Uretsky B F., Thygesen K, Armstrong P W. et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000 102 (6) 611-616
16. Beemath A, Stein P D., Skaf E, Al Sibae M R., Alesh I. Risk of venous thromboembolism in patients hospitalized with heart failure. Am J Cardiol 2006 98 (6) 793-795 (Pubitemid 44301013)
17. Howell M D., Geraci J M., Knowlton A A. Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study. J Clin Epidemiol 2001 54 (8) 810-816
18. Cokkinos D V., Haralabopoulos G C., Kostis J B., Toutouzas P K., HELAS investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006 8 (4) 428-432
19. Freudenberger R S., Hellkamp A S., Halperin J L. et al, SCD-HeFT Investigators. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2007 115 (20) 2637-2641
20. Loh E, Sutton M S., Wun C C. et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997 336 (4) 251-257
21. Dries D L., Rosenberg Y D., Waclawiw M A., Domanski M J. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997 29 (5) 1074-1080
22. Gibbs C R., Blann A D., Watson R D., Lip G Y. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001 103 (13) 1746-1751
23. Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley C M., Cleland J G. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994 127 (3) 607-612
24. Lip G Y., Gibbs C R. Does heart failure confer a hypercoagulable state? Virchows triad revisited. J Am Coll Cardiol 1999 33 (5) 1424-1426
25. Niebauer J, Volk H D., Kemp M et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999 353 (9167) 1838-1842
26. Felmeden D C., Lip G Y. The renin-angiotensin-aldosterone system and fibrinolysis. J Renin Angiotensin Aldosterone Syst 2000 1 (3) 240-244
27. Vaughan D E. Endothelial function, fibrinolysis, and angiotensin- converting enzyme inhibition. Clin Cardiol 1997 20 (11 suppl 2) II-34-II-37
28. Gavras H, Lever A F., Brown J J., Macadam R F., Robertson J I. Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet 1971 2 (7714) 19-22
29. Goodfield N E., Newby D E., Ludlam C A., Flapan A D. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999 99 (23) 2983-2985
30. Usalan C, Buyukhatipoglu H. A dynamic comparative study concerning the effects of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on the fibrinolytic system. Clin Appl Thromb Hemost 2008 14 (2) 203-209
31. Køber L, Torp-Pedersen C, Carlsen J E. et al, Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting- enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995 333 (25) 1670-1676
32. Yusuf S, Pepine C J., Garces C et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992 340 (8829) 1173-1178
33. Azevedo E R., Kubo T, Mak S et al. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation 2001 104 (18) 2194-2199
34. von Känel R, Dimsdale J E. Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo. Eur J Haematol 2000 65 (6) 357-369
35. Grignani G, Pacchiarini L, Zucchella M et al. Effect of mental stress on platelet function in normal subjects and in patients with coronary artery disease. Haemostasis 1992 22 (3) 138-146
36. Anfossi G, Trovati M. Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest 1996 26 (5) 353-370
37. Packer M, Coats A J., Fowler M B. et al, Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001 344 (22) 1651-1658 (Pubitemid 32479962)
38. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999 353 (9146) 9-13
39. Torp-Pedersen C, Poole-Wilson P A., Swedberg K et al, COMET Investigators. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failureCOMET. Am Heart J 2005 149 (2) 370-376
40. Kohno T, Yoshikawa T, Yoshizawa A et al. Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure. Cardiovasc Drugs Ther 2005 19 (5) 347-355
41. Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999 318 (7200) 1730-1737
42. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel J P. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998 98 (12) 1184-1191
43. Zee R Y., Cook N R., Cheng S, Erlich H A., Lindpaintner K, Ridker P M. Polymorphism in the beta2-adrenergic receptor and lipoprotein lipase genes as risk determinants for idiopathic venous thromboembolism: a multilocus, population-based, prospective genetic analysis. Circulation 2006 113 (18) 2193-2200
44. ODonnell J, Manning R A., Laffan M A. Beta-adrenergic receptor polymorphisms in patients with elevated factor VIII levels with venous thrombosis. Br J Haematol 2003 123 (1) 139-141
45. Nossent A Y., Dai L, Rosendaal F R., Vos H L., Eikenboom J C. Beta 2 adrenergic receptor polymorphisms: association with factor VIII and von Willebrand factor levels and the risk of venous thrombosis. J Thromb Haemost 2005 3 (2) 405-407
46. Lanfear D E., Jones P G., Marsh S, Cresci S, McLeod H L., Spertus J A. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA 2005 294 (12) 1526-1533
47. Dries D L., Domanski M J., Waclawiw M A., Gersh B J. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol 1997 79 (7) 909-913
48. Al-Khadra A S., Salem D N., Rand W M., Udelson J E., Smith J J., Konstam M A. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998 31 (4) 749-753
49. Al-Khadra A S., Salem D N., Rand W M., Udelson J E., Smith J J., Konstam M A. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998 31 (2) 419-425
50. de Boer R A., Hillege H L., Tjeerdsma G, Verheugt F W., van Veldhuisen D J. Both antiplatelet and anticoagulant therapy may favorably affect outcome in patients with advanced heart failure. A retrospective analysis of the PRIME-II trial. Thromb Res 2005 116 (4) 279-285
51. Cleland J G., Findlay I, Jafri S et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004 148 (1) 157-164
52. Anderson G M., Hull E. The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. Am Heart J 1950 39 (5) 697-702
53. Griffith G C., Stragnell R, Levinson D C., Moore F J., Ware A G. A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Ann Intern Med 1952 37 (5) 867-887
54. Harvey W P., Finch C A. Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. N Engl J Med 1950 242 (6) 208-211
55. Lip G Y., Gibbs C R. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm. Cochrane Database Syst Rev 2001 (4) CD003333
56. Cleland J G., Bulpitt C J., Falk R H. et al. Is aspirin safe for patients with heart failure? Br Heart J 1995 74 (3) 215-219
57. Teo K K., Yusuf S, Pfeffer M et al, ACE Inhibitors Collaborative Group. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002 360 (9339) 1037-1043